Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
S2 E11 — NASH-TAG Session 1 summary: Major Drugs in Development and Why Trials Fail
Manal Abdelmalek and Ian Rowe join Roger, Louise and Donna to review the morning that Vlad Ratziu and Michael Charlton both identified as the highlight session of NASH-TAG 2021.
The Friday morning session of NASH-TAG 2021 highlights advancing research for five major NASH drugs in development, explores the question why drug trials fail and wraps up with a rapid-fire session on promising data. Surfers were excited about some of the new drugs and found the presentations from Vlad Ratziu and Mary Rinella about why cirrhotic and non-cirrhotic drug trials fail to be particularly powerful and well-presented.
After the session, join SurfingNASH to sort out how what the data means, how the pieces fit together and what questions will require more exploration. If you send us any questions emerging from Session #1 or the podcast, we will try to review them during later NASH-TAG episodes.